The Longevity Digest 01/20 - 01/26

I'm cutting through the noise in longevity and anti-aging podcasts so you don't have to.

Welcome to The Longevity Digest.

The field moves fast. Too fast for most of us to track every breakthrough, every protocol update, every researcher’s latest findings. That’s where this comes in.

I’ve curated specific shows that consistently deliver evidence-based insights you can actually use. Think less fluff, more substance. The kind of information that changes how you practice or how you live.

Got a podcast that’s been delivering gold? Send it my way. I’m always hunting for voices that push the field forward.

This Newsletter Is Sponsored By Casa de Sante.

---

Dr Onyx MD PhD’s Insights on this week’s episodes

The GLP-1 Inflection Point: From Injection to Ecosystem

The conversation around GLP-1 therapy shifted dramatically this week from “should we use it?” to “how do we optimize, personalize, and eventually wean it?” Multiple podcasts converged on a nuanced reality: these drugs work powerfully, but they’re neither panacea nor permanent solution.

On Docs Who Lift and The Second Opinion Podcast, clinicians outlined the newly available oral semaglutide (Wegovy tablet) rollout, emphasizing practical realities that matter more than press releases. The oral formulation requires strict fasting administration with ≤4 oz water and a 30-minute wait before any other intake, a protocol that will test real-world adherence. The injectable-to-oral switch isn’t straightforward: moving from tirzepatide 5 mg or higher may require starting conservatively at oral semaglutide 9 mg rather than the exposure-equivalent 25 mg dose, because tolerability varies wildly by individual. Clinicians must titrate based on patient response, not just pharmacokinetic models.

But the true strategic insight came from the SURMOUNT-4 withdrawal data discussed on Docs Who Lift. After 36 weeks of tirzepatide treatment, patients randomized to placebo regained an average of ~14% body weight by week 88—yet responses were strikingly heterogeneous. Roughly 17% maintained most of their loss without medication, while others regained a large proportion. Crucially, cardiometabolic benefits, blood pressure, glycemia, triglycerides—waned with weight regain, and some blood pressure improvements appeared weight-independent yet still diminished without ongoing therapy. The implication: most patients will require chronic pharmacotherapy to sustain gains, much like we treat hypertension or dyslipidemia. Planning for dose reduction or discontinuation demands proactive monitoring and readiness to resume therapy.​

Yet pharmacologic GLP-1 may be only half the story. On The Human Upgrade, Dave Asprey presented the “internal pharmacy” framework: the gut microbiome can drive endogenous GLP-1 secretion through butyrate, a short-chain fatty acid produced when bacteria ferment resistant starch. The episode argues that structured meals (2–3/day with adequate protein and fiber), a 12–14-hour overnight fast, eliminating late-night eating and ultra-processed snacking, and gradual introduction of resistant starch (green banana flour, raw potato starch, tigernut flour) can upregulate native satiety signaling. While the podcast offered no peer-reviewed citations and leaned enthusiastically toward product mentions, the mechanistic claim aligns with established microbiome physiology: butyrate stimulates L-cells in the intestinal epithelium to release GLP-1. The strategic question for clinicians: can optimizing gut health reduce reliance on pharmacologic doses or facilitate eventual tapering? For patients struggling with injection aversion, side effects, or cost, this gut-centric approach offers an adjunctive or bridging strategy.​

Finally, on the neurodegenerative front, Dr. Ted Achacoso and Dave Asprey discussed GLP-1’s role beyond metabolism. Early trial data in Parkinson’s disease, specifically the lixisenatide NEJM study showed slowed clinical progression (MDS-UPDRS part III change: -0.04 vs +3.04 points in placebo). The proposed mechanism centers on microglial metabolic reprogramming: when microglia shift from pro-inflammatory M1 to reparative M2 states, they support rather than degrade neurons. GLP-1 agonists may bias this polarization by improving microglial mitochondrial function. This reframes GLP-1 drugs not just as appetite suppressants or cardiac protectors, but as potential neuroimmune modulators. Combined with emerging data in Alzheimer’s disease, the GLP-1 class is poised to expand far beyond its metabolic origins, provided we learn to integrate lifestyle, pharmacology, and long-term monitoring into a coherent care model.​

---

This Newsletter Is Sponsored By Casa de Sante.

For anyone on GLP-1 medications like Ozempic or Wegovy, Low FODMAP nutrition is non-negotiable. These medications can slow digestion and trigger bloating or nausea, so choosing gut-friendly products helps you stay comfortable while protecting muscle and metabolism. Physician-formulated by Dr Onyx MD PhD Certified in Obesity Management, this Low FODMAP lineup supports nutrient absorption, muscle defense, and overall digestive balance:

• Premium Protein Powder (Vegan Vanilla, Whey Vanilla, or Whey Chocolate) – helps preserve lean muscle during weight loss

• FODMAP Digestive Enzymes – improves absorption and reduces GI side effects

• Advanced Probiotic + Prebiotic Synbiotic Formula – supports a balanced gut microbiome

• Essential Vitamin & Mineral Complex – replenishes nutrients often depleted during rapid weight loss

• Gentle Colon Cleanse + Probiotic Support – aids regular elimination without irritation

All formulas are low FODMAP, non-GMO, and third-party tested—the ideal foundation for GLP-1 users focused on digestive comfort, metabolic health, and muscle preservation.

Because hormones and skin health are deeply connected, Dr Onyx MD PhD science-backed skincare supports barrier repair, hydration, and inflammation balance for healthy, resilient skin—especially during menopause or while using GLP-1 medications, when collagen loss and dryness can accelerate:

• HydraLift Collagen Complex – firms and smooths for youthful elasticity

• Antioxidant C+E Ferulic Radiance Serum – brightens and defends against oxidative stress

• Needle-Free Wrinkle Smoother – softens fine lines without irritation

• Ultra Retinol 10x + Bakuchiol Serum – boosts cell turnover with gentle plant retinol

• Advanced Retinol Eye Repair – targets puffiness and under-eye wrinkles

• Cellular Repair Growth Factor Peptides Serum – rejuvenates and supports skin repair

• Advanced Neck Lift Firming Complex – improves tone and texture along the jawline and neck

• Even Tone Brightening Cream – evens discoloration for radiant, balanced skin

---

Mitochondria and Metabolism: The New Neuroscience

A second strategic pivot emerged across multiple episodes: neurodegeneration is fundamentally a metabolic and immune disorder, not merely a protein misfolding disease. This upstream reframing from amyloid-centric to metabolic-centric has profound therapeutic implications.

Dr. Ted Achacoso introduced the Cell Danger Response (CDR) framework on The Human Upgrade. Developed by Robert Naviaux, the CDR describes how cells react to stressors—toxins, infections, psychological stress, mold, heavy metals by activating innate immunity and ER stress, shifting mitochondria toward fission and autophagy, hardening membranes, and signaling neighboring cells via extracellular ATP. When stressors persist or recur before full recovery, cells become stuck in CDR stages, creating metabolic separation and dyssynchrony between tissues. Achacoso’s clinical approach: methodically replete deficient metabolites (via metabolomics panels covering nutrients, amino acids, fatty acids), support circadian-restorative physiology (sleep, autonomic rebalancing), remove environmental stressors, and consider mitochondrial support such as low-dose methylene blue (8–16 mg in the morning) with appropriate precautions (avoid in G6PD deficiency and with serotonergic/MAO-inhibiting drugs).​

Methylene blue acts as an electron cycler that bypasses complex I of the mitochondrial electron transport chain. At low doses, it exhibits hormetic properties: enhancing cell respiration, acting as an antioxidant, and potentially aiding cognition and fatigue. While clinical trial data in humans remain limited, preclinical and small-scale human studies show promise in Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. The key insight: by restoring mitochondrial electron flow, methylene blue may help cells exit the CDR and resume normal metabolism offering symptom relief during the 6–12 months typically required for deeper metabolite repletion.​

This metabolic lens extends to neuroinflammation. On The Human Upgrade, Dave Asprey argued that Alzheimer’s, Parkinson’s, and aspects of autism/psychiatric symptoms reflect microglial immune–metabolic dysregulation driven by mitochondrial dysfunction and polarization from M2 (reparative) to M1 (pro-inflammatory) states. Targeting metabolism upstream—via GLP-1 agonists, 40 Hz gamma entrainment, near-infrared/red light, sleep optimization, exercise, ketogenic or metabolically supportive nutrition, and select nutraceuticals (e.g., urolithin A, CoQ10, rosmarinic acid)—shows promise for re-biasing microglia toward support rather than destruction. The episode highlighted emerging data on 40 Hz light/sound stimulation (gamma entrainment using sensory stimuli, or GENUS), which in rodent models reduces amyloid-β pathology and in small human studies improves sleep and daily living activities in Alzheimer’s patients. The mechanism: 40 Hz oscillations may drive microglial activation patterns that enhance amyloid clearance and increase glymphatic flow. While methodological variability and contradictory findings in some mouse studies underscore the need for further investigation, the conceptual shift is clear: neurodegeneration may be treatable by restoring cellular bioenergetics and immune balance, not just clearing plaques.​

Dr. Lisa Mosconi’s discussion with Peter Attia extended this metabolic framework to women’s Alzheimer’s risk. Women account for roughly two-thirds of Alzheimer’s cases, a disparity not fully explained by longevity. Menopause is a brain event: declining estradiol impacts brain glucose metabolism (FDG-PET), hippocampal structure, cerebral blood flow, and immune signaling. Novel PET imaging suggests estrogen receptor density in the brain and pituitary upregulates through approximately age 65, implying a broader therapeutic window than older rodent models indicated. The timing and formulation of hormone therapy matter profoundly: the Women’s Health Initiative Memory Study (WHIMS) found increased dementia risk when conjugated equine estrogens plus medroxyprogesterone acetate (CEE+MPA) was initiated in older women, while observational data suggest starting transdermal estradiol with micronized progesterone within 10 years of the final menstrual period—especially estrogen-only after hysterectomy—may reduce dementia risk. Transdermal estradiol plus micronized progesterone likely carries a more favorable vascular and metabolic profile than oral CEE+MPA.​​

Genetics amplify sex-specific risk: APOE4 confers a larger dementia risk increase for women (approximately 4× for heterozygotes, 12–15× for homozygotes vs. noncarriers) than for men, underscoring the need for sex-stratified risk assessment. Mosconi emphasized that preclinical Alzheimer’s disease can be detected decades before symptoms via advanced imaging (amyloid PET, MRI) and blood-based biomarkers (plasma p-tau, Aβ42/40). She previewed the CARE initiative—a $50M Wellcome Leap program designed to harmonize global female-specific data and prospectively track biomarker changes with interventions though details on this program were not independently verified in available literature. Regardless, the strategic takeaway stands: for many women, Alzheimer’s risk begins to diverge in midlife, driven by neuroendocrine transitions; proactively addressing menopausal symptoms, optimizing vascular–metabolic health (blood pressure, insulin sensitivity, sleep), and timing hormone therapy appropriately can materially influence long-term brain aging.​

Precision Prevention: Moving Beyond Population Norms

The third strategic pivot reframes prevention from population-based guidelines to individualized, biomarker-driven risk detection. Multiple episodes argued that “normal-for-age” lab results can mask early disease, delaying intervention when it would be most effective.

On Health Longevity Secrets, Dr. Sandeep Palakodeti outlined the problem: American medicine excels at acute disease but underinvests in prevention; standard panels often miss early cardiometabolic risk. He advocated measuring ApoB (apolipoprotein B) and lipoprotein(a) [Lp(a)] at least once, alongside insulin resistance assessment beyond HbA1c—such as fasting insulin with HOMA-IR or an LP-IR score. ApoB provides an integrated measure of all atherogenic lipoproteins (each LDL, VLDL, and Lp(a) particle carries one ApoB molecule); elevated ApoB predicts cardiovascular events more accurately than LDL-C alone, especially when they are discordant. Multiple large cohort studies and Mendelian randomization analyses confirm ApoB’s causal role in atherosclerotic cardiovascular disease.​

Lp(a) is a genetically determined, largely LDL-like particle with atherogenic and prothrombotic properties; levels remain stable across a lifetime, enabling one-time screening. Approximately 20% of the population has elevated Lp(a) (>50 mg/dL or >125 nmol/L), yet screening rates remain low: only 1.1% of U.S. adults and 2.0% of those with established cardiovascular disease had Lp(a) testing in one large database analysis. European and Canadian guidelines now recommend universal Lp(a) screening in all adults, and the U.S. is moving in that direction as evidence mounts. Elevated Lp(a) acts as a risk enhancer: when present, it justifies more aggressive LDL-C lowering and lifestyle modification. Emerging therapies—including siRNA and antisense oligonucleotides—may soon provide Lp(a)-specific lowering, making identification even more clinically actionable.

Dr. Palakodeti’s actionable recommendation: for midlife or at-risk adults, order one-time Lp(a) and ApoB, add insulin resistance testing (fasting insulin with HOMA-IR or LP-IR), and use results to initiate a personalized plan prioritizing the “core four” lifestyle pillars—sleep optimization, protein-forward nutrition, resistance/VO₂max training, and mental health/relationship support. This approach shifts the paradigm from reactive treatment to proactive health creation.​

The podcast also introduced the EASI framework (Evidence, Accessibility, Safety, Intent) for evaluating advanced or “biohacking” therapies—such as rapamycin, peptides, red light, hyperbaric oxygen. Core behaviors must be optimized first; only then should clinicians and patients consider interventions with clear stop criteria. This structured vetting prevents the common trap of layering expensive, unproven therapies atop poor foundational habits.​

In cardiology, This Week in Cardiology reinforced the importance of operator and center volume for structural heart interventions. Registry data showed that low-volume TAVR (<15/year) and M-TEER (<8/year) operators had worse adjusted 30-day outcomes versus high-volume operators, with effect sizes persisting across hospital-volume strata and after excluding operators’ first 10 cases. This supports centralization, robust mentorship, and performance monitoring—not expanding low-volume programs for convenience. The strategic implication: precision prevention includes precision referral, directing patients to high-volume centers where outcomes data justify confidence.​

On Huberman Lab, Dr. Andrew Huberman and Dr. David Eagleman explored how to engineer behavior change using precommitment strategies (also called “Ulysses contracts”). Environment design, social accountability, and financial stakes—such as lockboxes for phones, removing alcohol from the home, limiting cash, enlisting gym buddies—reliably improve adherence. The neuroscience is clear: directing plasticity with intention (via neuromodulators like acetylcholine acting in concert during focused attention) beats indiscriminate plasticity. For instance, dopamine agonists in Parkinson’s disease can trigger impulse-control disorders—pathological gambling, compulsive shopping, hypersexuality—because they boost plasticity broadly, not selectively. This warrants proactive screening and counseling at each visit. The clinical lesson: design systems that align present actions with future goals, because willpower alone is insufficient.​​

Finally, The Human Upgrade highlighted two policy-level shifts with immediate clinical relevance. The 2025–2030 U.S. Dietary Guidelines (as previewed in the podcast) emphasize whole-food protein, vegetables, fruits, healthy fats, whole grains, and full-fat dairy while calling for sharp limits on ultra-processed foods and added sugars. This shift gives clinicians a strong, policy-aligned foundation for nutrition counseling and institutional advocacy. Whole milk was reportedly restored to U.S. school meal programs, aligning with the new guidance and potentially improving satiety while reducing added sugar intake in children. Additionally, OpenAI launched ChatGPT Health, enabling users to upload medical records and integrate wellness data (e.g., Apple Health, MyFitnessPal) for visit summaries, lab interpretation support, and better-informed clinician questions—positioned as a coaching tool, not a clinical decision-maker. While the technology’s accuracy and liability framework remain to be proven, the strategic implication is clear: patients will arrive with AI-generated summaries and questions; clinicians must be prepared to validate, contextualize, and correct these outputs.​

The longevity field is also moving toward rigorous endpoints. A new tirzepatide trial will directly test whether the drug slows biological aging using multiple DNA methylation clocks as primary endpoints, with functional measures (grip strength, walking capacity) to clarify GLP-1’s role beyond weight loss. This signals a maturation: moving from surrogate markers to biological age as a measurable, modifiable outcome.​

This weeks episodes:

1. Health Longevity Secrets

When Normal Labs Are Unhealthy with Sandeep Palakodeti MD

Published: 2026-01-20

URL: Listen Here

Summary

This episode argues that American medicine is optimized for acute disease rather than health creation, and that ‘normal’ lab results can conceal early cardiometabolic risk. Dr. Sandeep Palakodeti outlines a proactive, concierge model built on the core lifestyle pillars, deeper risk assessment (ApoB, Lp(a), insulin resistance), and a structured way to vet advanced therapies, while highlighting how AI plus clinicians can scale prevention. The goal is to extend one’s prime—combining later-life wisdom with youthful physiology—by treating health as the ultimate asset.

Key Takeaways

• Normal-for-age labs can mask early disease; go beyond standard panels to assess ApoB, lipoprotein(a), and insulin resistance, and interpret data longitudinally and individually.

• U.S. healthcare excels at acute care but underinvests in prevention; longer visits in a concierge, interdisciplinary model enable proactive, personalized health creation.

• Foundational “core four” behaviors—sleep, nutrition, exercise, and relationships/mental health—must be optimized before pursuing advanced or ‘biohacking’ therapies.

• Use a structured evidence screen (EASI: Evidence, Accessibility, Safety, Intent) and clear stop criteria to evaluate longevity interventions such as rapamycin, peptides, red light, and hyperbaric oxygen.

• AI will rapidly augment clinicians by synthesizing vast patient and wearable data and automating simple care, while human clinicians remain essential for complex, values-based decisions.

Clinical Insight

Relying on population ‘normal’ ranges often delays prevention; individualized risk detection—especially measuring ApoB and lipoprotein(a) at least once and assessing insulin resistance beyond A1c—enables earlier, more effective cardiometabolic prevention.

Actionable Takeaway

For midlife or at-risk adults, order one-time lipoprotein(a) and ApoB, add insulin resistance testing (e.g., fasting insulin with HOMA-IR or an LP-IR score), and use results to initiate a personalized plan prioritizing sleep optimization, protein-forward nutrition, resistance/VO2max training, and mental health/relationship support.

2. The Human Upgrade: Biohacking for Longevity & Performance

Inside the Mind of the Mad Scientist Rewriting Aging : 1401

Published: 2026-01-20

URL: Listen Here

Summary

Dave Asprey and Dr. Ted Achacoso outline a metabolomics-driven, cell-focused approach to health that centers on the Cell Danger Response and mitochondrial optimization, with practical tools like methylene blue and cordycepin for symptom relief during longer-term repletion. The discussion offers clinicians a framework for sequencing interventions around daily metabolic states, gut and immune inputs, and mitochondrial targets, while noting trade-offs (e.g., metformin, LDL/LPS). Some claims are exploratory or product-oriented, and dosing evidence for certain agents varies across studies.

Key Takeaways

• Health Optimization Medicine (HOMe) is a cell-centric, metabolomics-guided framework that focuses on restoring the root causes of health (balanced metabolites, mitochondrial function, autonomic balance) rather than treating organ-specific disease; meaningful optimization typically takes 6–12 months with symptom support along the way.

• The Cell Danger Response (CDR) frames how cells react to stressors (toxins, infections, psychological stress, mold, heavy metals): innate immunity and ER stress activate, mitochondria shift toward fission/autophagy, membranes harden, extracellular ATP signals neighboring cells; recovery hinges on rest, autonomic rebalance, and correcting metabolite drivers.

• Daily ‘summer’ (growth/anabolic) and ‘winter’ (repair/catabolic) metabolic states can be mapped to nutrient signals (e.g., leucine vs. alpha-lipoic acid) and feeding cycles; post-prandially, transient inflammation is expected, which underscores the value of timing, meal composition, and gut integrity.

• Mitochondrial support featured prominently: methylene blue can act as an electron cycler that bypasses complex I, potentially aiding cognition and fatigue; metformin’s complex I inhibition and VO2max effects were noted as trade-offs to monitor.

• Clinical nuances discussed included LDL’s role in scavenging LPS (overly aggressive LDL lowering may impair endotoxin clearance) and cordycepin (an adenosine-like compound from Cordyceps militaris) as a potential aid for slow-wave sleep, inflammation modulation, and ongoing oncology research.

Clinical Insight

Viewing chronic, multisystem complaints through the lens of the Cell Danger Response and mitochondrial health—then methodically repleting deficient metabolites, supporting circadian-restorative physiology, and removing stressors—can improve resilience and function across organ systems without disease-centric prescribing.

Actionable Takeaway

For patients with chronic fatigue, brain fog, or toxin/mold exposure, evaluate metabolomics (nutrients, amino acids, fatty acids), gut integrity, and autonomic balance; prioritize sleep and circadian timing, remove stressors, and consider mitochondrial support such as low-dose methylene blue (e.g., 8–16 mg in the morning) with appropriate precautions (avoid in G6PD deficiency and with serotonergic/MAO-inhibiting drugs), monitoring response and adjusting alongside lifestyle interventions.

3. Docs Who Lift

Oral GLP-1 (Wegovy) Is Here: Dosing, Switching, and What to Expect

Published: 2026-01-20

URL: Listen Here

Summary

This episode explains how to dose and switch to the newly available oral Wegovy, emphasizing fasting administration, practical conversion from injectables, and individualized titration based on tolerability and cost. It also reviews SURMOUNT-4 withdrawal findings, highlighting heterogeneous weight trajectories after stopping tirzepatide and the frequent need for maintenance therapy to preserve cardiometabolic gains. Note: Direct head-to-head switch protocols and some pricing/coverage details are still evolving, so recommendations reflect current label guidance plus real-world clinical judgment.

Key Takeaways

• Oral Wegovy (semaglutide tablets) uses SNAC absorption technology and requires roughly 10× the dose of injectable semaglutide; the labeled dose-escalation is 1.5 mg → 4 mg → 9 mg → 25 mg, and tablets must be taken fasting with a very small amount of water (≤4 oz) and a ≥30-minute wait before any other intake.

• Practical switching: Injectable Wegovy 2.4 mg weekly ≈ Oral Wegovy 25 mg daily exposure; when switching from tirzepatide (Zepbound) 5 mg or higher, many clinicians may conservatively start at 9 mg oral Wegovy and titrate based on tolerance.

• Tolerability varies by individual; some patients appear to tolerate tirzepatide better than semaglutide, so switching and titration should be individualized with shared decision-making and close follow-up.

• SURMOUNT-4 withdrawal data: after a 36-week tirzepatide lead-in, patients randomized to placebo regained ~14% body weight on average by 88 weeks, but responses were heterogeneous—about 17% maintained most of their loss, while others regained a large proportion; continued therapy produced an additional ~5.5% average loss.

• Cardiometabolic benefits (blood pressure, glycemia, triglycerides) tended to wane with weight regain after stopping therapy; some blood pressure benefit appears weight-independent and may diminish even without full weight regain, underscoring chronic-disease management.

Clinical Insight

Most patients will require ongoing anti-obesity pharmacotherapy to sustain weight and cardiometabolic benefits; if attempting dose reduction or discontinuation, plan proactive monitoring and be ready to resume or adjust therapy, as withdrawal responses are highly individualized.

Actionable Takeaway

When initiating or switching to oral semaglutide, set a clear plan: GLP-1–naïve patients start at 1.5 mg daily and escalate every 4 weeks (1.5 → 4 → 9 → 25 mg) as tolerated; if switching from SQ semaglutide 2.4 mg consider 25 mg oral (or 9 mg if tolerability is uncertain), and from tirzepatide ≥5 mg consider 9 mg to start—counsel to take on an empty stomach with ≤4 oz water and wait ≥30 minutes before any food, drink, or other meds (coordinate carefully with levothyroxine timing).

4. The Second Opinion Podcast with Dr. Paul Kolodzik

New Hope: Unpacking the Weygovy Pill with Dr. Paul Kolodzik

Published: 2026-01-22

URL: Listen Here

Summary

Dr. Kolodzik reviews the newly available oral semaglutide (“Wegovy pill”), comparing efficacy, dosing logistics, eligibility, and evolving cost/access, and underscores combining pharmacotherapy with diet, CGM use, and strength training. The episode anticipates increasing competition and payer negotiations that could further reduce costs and expand access. Note: Some indications and pricing/coverage details discussed may reflect evolving evidence, local policies, or pending regulatory decisions; verify against current labeling and payer criteria.

Key Takeaways

• The episode discusses the new oral formulation of semaglutide for weight loss (referred to as the “Wegovy pill”), noting it is the same active ingredient as injectable Wegovy and related to the diabetes pill Rybelsus, potentially broadening access for patients who prefer pills over injections.

• Reported trial efficacy for the pill is slightly lower than the injection (~13% vs ~15% mean weight loss), and the oral version requires strict morning dosing on an empty stomach with water and no food/coffee/other meds for ~30 minutes; daily adherence and GI tolerability were emphasized.

• Access and cost: promotional cash pricing was cited as ~$149/month for the first two titration months, then ~$349/month at higher doses; discount programs may exclude Medicare/Medicaid, with expectations that competition and payer negotiations could lower costs and expand coverage.

• Eligibility aligns with anti-obesity criteria (BMI ≥30, or ≥27 with comorbidity); the episode also mentions additional/related indications (e.g., fatty liver disease, sleep apnea, and secondary prevention after cardiac events), alongside the trend of manufacturers seeking broader labeled indications.

• Long-term use is likely but should be paired with lifestyle interventions (low-carbohydrate nutrition, intermittent fasting, strength training, and CGM-guided monitoring), with the possibility of tapering off in selected patients.

Clinical Insight

An oral semaglutide option for obesity may increase uptake among injection-averse patients, but its real-world effectiveness depends on selecting eligible patients, counseling on precise administration requirements and side effects, and embedding treatment within structured lifestyle therapy.

Actionable Takeaway

For eligible patients (BMI ≥30 or ≥27 with comorbidity), discuss oral semaglutide as an alternative to injections; verify coverage, initiate low-dose therapy with monthly titration, and instruct patients to take it on waking with a small amount of water and avoid food/coffee/other meds for ~30 minutes, while concurrently implementing a defined nutrition and strength-training plan and monitoring GI tolerability.

5. Huberman Lab

Essentials: Therapy, Treating Trauma & Other Life Challenges | Dr. Paul Conti

Published: 2026-01-22

URL: Listen Here

Summary

This episode distills core principles of trauma care: define trauma by its lasting impact, recognize shame/guilt and repetition compulsion as key drivers, and prioritize language-based processing within strong therapeutic rapport. It underscores judicious use of medications, emerging promise of clinician-guided psychedelic and MDMA-assisted approaches, and the nonnegotiable role of basic self-care.

Key Takeaways

• Trauma is best defined as an experience that overwhelms coping and produces durable changes in brain function and behavior—often expressed as shifts in mood, anxiety, sleep, vigilance, and physical health.

• Reflexive shame and guilt following trauma are evolutionarily rooted but maladaptive in modern life; they drive avoidance, which prevents healing and sustains symptoms.

• Repetition compulsion—unconsciously recreating traumatic dynamics to ‘make it right’—is common; naming and processing the original trauma disrupts these cycles.

• Putting trauma into words (speaking or writing) with a trusted other or clinician helps shift from self-blame to compassion, enables grieving, and reduces arousal; pacing and titration are key to avoid re-traumatization.

• Therapeutic rapport is the most important ingredient—modality should be flexible; medications can aid distress tolerance and rumination but are often overused; carefully guided psychedelic/MDMA-assisted therapy shows promise; foundational self-care (sleep, nutrition, light, healthy relationships) is essential.

Clinical Insight

The most impactful clinical move is to help patients safely articulate and examine trauma—explicitly targeting shame and guilt—because bringing the trauma into compassionate, present-focused awareness reduces limbic-driven avoidance and reenactment, enabling durable symptom improvement across mood, anxiety, and behavior.

Actionable Takeaway

Assign a brief, structured trauma-narrative exercise: ask the patient to write for 10–15 minutes about (1) what happened, (2) how it changed their self-talk and daily functioning, and (3) what they would say to a friend who endured the same event; review it together in session, using grounding and pacing to prevent overwhelm and to cultivate self-compassion.

6. The Human Upgrade: Biohacking for Longevity & Performance

This Brain Trick Feels Like Cheating (Do THIS) : 1402

Published: 2026-01-22

URL: Listen Here

Summary

This episode centers on microglia as pivotal regulators of brain health and disease, arguing that mitochondrial and metabolic status drive their polarization and, by extension, neurodegeneration and behavior. It highlights upstream metabolic interventions (lifestyle, GLP‑1 agonists, 40 Hz gamma entrainment, infrared light) and gut–environment influences as levers to shift microglia toward repair. Note: Some claims are anecdotal or enthusiastic (e.g., the degree of Parkinson’s arrest); clinicians should verify details in primary studies.

Key Takeaways

• Neurodegeneration (e.g., Alzheimer’s, Parkinson’s) and aspects of autism/psychiatric symptoms are increasingly framed as disorders of immune–metabolic dysregulation in the brain, driven by microglial mitochondrial dysfunction and polarization from reparative M2 to pro‑inflammatory M1 states.

• Targeting metabolism upstream—rather than solely protein aggregates—shows promise: GLP‑1 receptor agonists can modulate microglial metabolism and reduce cravings; early randomized data in Parkinson’s suggest slowed clinical progression with GLP‑1 therapy.

• Nonpharmacologic modalities can help re‑bias microglia toward a supportive state: 40 Hz light/sound (gamma entrainment), near‑infrared/red light, sleep optimization, exercise, ketogenic or metabolically supportive nutrition, and select nutraceuticals (e.g., urolithin A, CoQ10, rosmarinic acid, dihydromyricetin, low‑dose lithium, nicotine).

• Gut–brain and environment–brain pathways matter: microbiome‑derived short‑chain fatty acids (higher propionate vs. butyrate), mold susceptibility, pesticides (glyphosate, paraquat), PM2.5, and cyanobacterial toxins can activate microglia and raise neurodegenerative risk.

• Systemic inflammation weakens prefrontal top‑down control (favoring amygdala‑driven impulsivity); GLP‑1 drugs may broadly reduce reward‑seeking behaviors (food, alcohol, gambling), implying large clinical and societal effects beyond weight.

Clinical Insight

Reframe neurodegenerative and related neurobehavioral conditions as immune–metabolic illnesses centered on microglial mitochondrial function; prioritize restoring systemic and neuroinflammation balance and metabolic health to influence disease trajectory, rather than focusing only on downstream proteinopathies or symptom control.

Actionable Takeaway

For patients with cognitive, movement, or impulsivity symptoms, assess and optimize metabolic and inflammatory status (fasting glucose/insulin, HbA1c, hs‑CRP; consider CGM), implement a metabolically supportive program (sleep, exercise, time‑restricted or ketogenic nutrition as appropriate), and consider adjunctive 40 Hz light/sound stimulation; individualize pharmacologic add‑ons (e.g., GLP‑1 RA) when clinically indicated and safe.

7. The Human Upgrade: Biohacking for Longevity & Performance

Biohacking News Weekly Update : 1403

Published: 2026-01-23

URL: Listen Here

Summary

This episode highlights system-level shifts in nutrition policy (2025–2030 Dietary Guidelines; whole milk in schools), emerging longevity research favoring combination strategies, and the debut of an AI health data layer (ChatGPT Health) to improve patient–clinician interactions. It also previews a tirzepatide trial measuring biological aging via DNA methylation clocks, signaling a more rigorous standard for longevity claims.

Key Takeaways

• The 2025–2030 U.S. Dietary Guidelines emphasize real foods—whole-food protein, vegetables, fruits, healthy fats, whole grains, and full-fat dairy—while calling for sharp limits on ultra-processed foods and added sugars; this shift will influence schools, federal programs, labeling, and procurement.

• A preclinical study in frail, aged male mice found that combining oxytocin with a compound called A5I extended remaining lifespan by ~73% and improved physical function, reinforcing a multi-target, phased approach to longevity rather than single-agent solutions.

• OpenAI launched ChatGPT Health, enabling users to upload medical records and integrate wellness data (e.g., Apple Health, MyFitnessPal) for visit summaries, lab interpretation support, and better clinician questions—positioned as a coaching tool, not a clinical decision-maker.

• Whole milk is reportedly restored to U.S. school meal programs via the Whole Milk for Healthy Kids Act, aligning with the new dietary guidance and potentially improving satiety and reducing added sugar and waste in school meals.

• A new clinical trial will directly test whether tirzepatide can slow biological aging using multiple DNA methylation clocks as primary endpoints, with functional measures (e.g., grip strength, walking capacity) to clarify GLP-1 drugs’ role in longevity.

Clinical Insight

Federal guidance now validates a whole-food, higher-protein, healthy-fat dietary pattern (including full‑fat dairy) and limiting ultra‑processed foods, giving clinicians a strong policy-aligned foundation for nutrition counseling and institutional advocacy while emerging longevity data suggest multi-modal, phased interventions may outperform single agents.

Actionable Takeaway

Integrate a brief ultra-processed food screen into routine visits and set one specific substitution goal (e.g., replace sugary beverages/snacks with water and a whole‑food protein option; consider full‑fat dairy when appropriate) to align patient counseling with the 2025–2030 Dietary Guidelines.

8. This Week in Cardiology

Jan 23 2026 This Week in Cardiology

Published: 2026-01-23

URL: Listen Here

Summary

Registry data link higher operator volume to better 30-day outcomes for TAVR and M-TEER, supporting centralization and structured training/mentorship. Older male endurance athletes show a notable burden of ventricular arrhythmias tied to myocardial fibrosis on CMR, but findings do not justify routine screening absent symptoms. An NHANES analysis comparing 10-year versus 30-year ASCVD risk highlights tensions between long-horizon statin strategies and guideline-based 10-year thresholds prioritizing lifestyle changes, with the host favoring the latter given uncertainty in 30-year projections.

Key Takeaways

• In a mandated national STS/ACC TVT Registry analysis, low-volume TAVR (<15/year) and M-TEER (<8/year) operators had worse adjusted 30-day outcomes versus high-volume operators (TAVR mortality OR ~1.13; TAVR complications OR ~1.09; M-TEER complications OR ~1.31) and inferior process metrics.

• The volume–outcome association persisted across hospital-volume strata and after excluding an operator’s first 10 cases, supporting causal inference and arguing for centralization, robust mentoring, and performance monitoring rather than expanding low-volume programs for convenience.

• Among 106 asymptomatic older male endurance cyclists with implantable loop recorders, 23% had ventricular arrhythmias (3 sustained VT); arrhythmias correlated with CMR-detected myocardial fibrosis and atypical exercise PVCs, but routine screening of athletes was not supported.

• An NHANES-based analysis using AHA’s PREVENT 30-year risk equation identified many adults with low 10-year but high 30-year ASCVD risk; expanding statins by 30-year risk could treat ~2.5 million additional adults with modest 10-year absolute benefit (10-year NNT ≈78), prompting debate over appropriate time horizons vs guideline-based 10-year thresholds and lifestyle-first approaches.

• Listener feedback on WITHDRAW-AF emphasized that AF-mediated cardiomyopathy remains unproven as a distinct entity; any GDMT withdrawal after EF recovery should be selective, closely monitored, and not routine.

Clinical Insight

For structural heart interventions (TAVR, M-TEER), operator and center volume strongly influence short-term outcomes; concentrating care in high-volume programs and ensuring structured mentorship for newer operators can improve patient safety and efficacy.

Actionable Takeaway

When arranging TAVR or M-TEER, preferentially refer patients to high-volume operators/centers and use available registry or program-reported volumes to guide referral decisions.

9. The Human Upgrade: Biohacking for Longevity & Performance

The Natural Ozempic In Your Gut (Eat THIS To Switch It On) : 1404

Published: 2026-01-25

URL: Listen Here

Summary

This episode argues that the body has a “natural Ozempic” via endogenous GLP-1 signaling that can be reactivated by improving gut health and feeding the microbiome with resistant starch to boost butyrate. It contrasts pharmacologic GLP-1 agonists with dietary and lifestyle strategies (structured meals, sleep/stress optimization, and gradual introduction of resistant starch) to promote satiety and sustainable weight control. Note: the episode offers mechanistic claims and brand mentions but provides no specific peer‑reviewed citations in the transcript.

Key Takeaways

• Appetite and weight regulation are driven by gut–brain hormones (not just calorie math); GLP-1 released from the intestine is central to satiety, glycemic control, and meal termination.

• GLP-1 receptor agonists (e.g., semaglutide/Ozempic) suppress appetite but, per the episode, do not repair endogenous signaling and may be associated with side effects, muscle loss, and rebound hunger/weight when discontinued.

• Microbiota-derived butyrate—produced when gut bacteria ferment resistant starch—can stimulate endogenous GLP-1 secretion and support steadier energy and reduced cravings.

• The episode advocates restoring gut signaling via structured meals (2–3/day), adequate protein and fiber, limiting snacking/ultra-processed foods/late-night eating, managing stress and sleep, light post-meal activity, and a 12–14-hour overnight fast.

• Resistant starch sources suggested include green banana flour, acacia gum, tigernut flour, and small amounts of raw potato starch; introduce gradually to GI tolerance, along with supportive fats (e.g., butter/ghee/MCT) and modest prebiotic vegetables (onion/garlic/asparagus).

Clinical Insight

In patients struggling with appetite and weight, addressing satiety biology—particularly by supporting endogenous GLP-1 signaling through gut health and fermentable fibers (resistant starch → butyrate)—may complement or, in select cases, reduce reliance on GLP-1 pharmacotherapy; ensure adequate protein and monitor for GI tolerance and muscle preservation.

Actionable Takeaway

Trial a 4-week protocol: shift to 2–3 structured meals/day with protein and fiber, stop eating ≥3 hours before bedtime to create a 12–14-hour overnight fast, and add a small daily dose of resistant starch (e.g., 1 teaspoon green banana flour or raw potato starch in week 1), increasing slowly to 1–2 small servings/day by weeks 2–3 as tolerated while monitoring GI symptoms and satiety.

10. Huberman Lab

Science & Tools of Learning & Memory | Dr. David Eagleman

Published: 2026-01-26

URL: Listen Here

Summary

This episode explores how the brain changes itself through neuroplasticity and how to leverage novelty, attention, and precommitment strategies to learn better, change behavior, and preserve cognition. It clarifies common misconceptions about time perception under stress, offers a unifying view of sensory substitution/addition, and presents a testable theory of dreaming as visual-cortex defense during darkness—all with practical and clinical implications. Note: this synthesis is based on the provided transcript excerpt.

Key Takeaways

• Neuroplasticity is lifelong and experience-dependent: cortex is a general-purpose ‘one-trick pony’ whose function is defined by its inputs; novelty and challenge keep adult brains changing, whereas practiced, easy tasks drive efficiency but little change.

• Cognitive reserve matters: sustained social engagement and diverse, effortful activities can mask clinical expression of neuropathology (e.g., in the Religious Orders Study, some nuns had Alzheimer’s pathology without cognitive symptoms), underscoring the value of novelty and social interaction across the lifespan.

• Directed plasticity beats indiscriminate plasticity: neuromodulators act in concert (with acetylcholine critical for focal adult learning); enhancing plasticity (e.g., via drugs or psychedelics) can have unintended effects—dopamine agonists in Parkinson’s can trigger impulse-control disorders such as pathological gambling.

• Perceived ‘slow motion’ during trauma reflects denser memory encoding (amygdala-mediated), not faster real-time perception; novelty and attention increase subjective time by creating more memorable “footage.”

• Precommitment (‘Ulysses contracts’) aligns present actions with future goals—environment design, social accountability, and financial stakes (e.g., lockboxes for phones, removing alcohol from the home, limiting cash, gym buddies) reliably improve adherence and behavior change.

Clinical Insight

Encourage and prescribe lifelong, socially embedded novelty and cognitively effortful activities to build cognitive reserve, while recognizing that pharmacologically boosting plasticity can carry risks—e.g., dopamine agonists in Parkinson’s disease are associated with impulse-control disorders and warrant proactive screening and counseling.

Actionable Takeaway

For patients with Parkinson’s disease on dopamine agonists, implement routine screening for impulse-control disorders (e.g., gambling, compulsive shopping, hypersexuality) at each visit, and counsel patients and families upfront about these risks with a clear plan to adjust therapy if behaviors emerge.

11. The Peter Attia Drive

#381 ‒ Alzheimer’s disease in women: how hormonal transitions impact the female brain, the role of HRT, genetics, and lifestyle on risk, and emerging diagnostics and therapies | Lisa Mosconi, Ph.D.

Published: 2026-01-26

URL: Listen Here

Summary

This episode explores why women bear a disproportionate burden of Alzheimer’s disease, highlighting menopause as a pivotal neurobiological transition that initiates midlife brain changes detectable with advanced imaging and biomarkers. It reviews nuanced evidence on the timing and formulation of hormone therapy, sex-specific genetic risk (APOE4), and the CARE initiative’s plan to use biomarker-guided strategies to cut women’s Alzheimer’s risk, emphasizing lifestyle optimization as the foundational intervention. Some findings (e.g., estrogen receptor PET patterns and GLP‑1 neuroprotection) are emerging and require further prospective validation.

Key Takeaways

• Alzheimer’s disease affects women about 2:1 vs men, and this gap is not fully explained by longevity; women show earlier, midlife-onset brain changes (metabolic, structural, immune) and may mask early deficits due to a higher verbal memory reserve.

• Menopause is a brain event: declining estradiol impacts brain energy (FDG-PET), structure (e.g., hippocampus), blood flow (ASL), and immune signaling; novel PET work suggests estrogen receptor density in the brain/pituitary upregulates through roughly age 65, implying a broader therapeutic window than rodent models suggest.

• Hormone therapy effects depend on timing and formulation: WHIMS found increased dementia risk when CEE+MPA was initiated in older women, while observational data suggest starting within 10 years of the final menstrual period—especially estrogen-only after hysterectomy—may reduce dementia risk; transdermal estradiol plus micronized progesterone likely carries a more favorable vascular risk profile than oral CEE+MPA.

• Genetics modify risk by sex: APOE4 confers a larger increase in dementia risk for women (approx. 4x for heterozygotes; 12–15x for homozygotes vs noncarriers) than for men, underscoring the need for sex-specific risk stratification and counseling.

• Preclinical AD can be detected decades before symptoms via imaging and blood-based biomarkers (e.g., amyloid PET, MRI, plasma p-tau, Aβ42/40); CARE (a $50M Wellcome Leap program) will harmonize global female-specific data and prospectively track biomarker changes with interventions, while lifestyle management (sleep, blood pressure, insulin sensitivity, physical activity) remains the foundation of prevention.

Clinical Insight

For many women, Alzheimer’s risk begins to diverge in midlife, driven by neuroendocrine transitions of menopause; proactively addressing menopausal symptoms and timing/formulation of menopausal hormone therapy in the context of vascular–metabolic health and sex-specific genetics can materially influence long-term brain aging and dementia risk.

Actionable Takeaway

During perimenopause/early postmenopause, incorporate a brain-health-focused visit: assess AD risk (family history, APOE status if appropriate), optimize vascular–metabolic factors (BP, insulin resistance, sleep), and have an informed discussion about menopausal hormone therapy—favoring transdermal estradiol with micronized progesterone when indicated—while tracking response with validated blood biomarkers (e.g., plasma p‑tau and Aβ42/40) and baseline brain MRI if clinically warranted.

Stay connected with Dr Onyx MD PhD for clinical insights and wellness tools that bridge science and everyday care:

Instagram ✦ X (Twitter) ✦ LinkedIn ✦ Website

From Insights to Action

Knowledge without execution changes nothing. The insights above only reach their full potential when integrated into a strategic, personalized plan. That’s where two offerings come in:

---

Personalized Medical AI Chatbot

Healthcare complexity is overwhelming. Clinical studies, conflicting guidelines, and fragmented records leave most patients paralyzed.

Deploy your Dr Onyx MD PhD Medical AI Chatbot—a personalized architecture that synthesizes your medical history, the latest research, and your unique condition into clear, actionable insights.

It’s not a replacement for your doctors—it’s your secret weapon for making better decisions and becoming the CEO of your own care.

👉 Deploy your Medical AI Chatbot today and take control of your health narrative

Premium Longevity Program

For people who know their most valuable asset is their health.

This year-long partnership delivers clarity, accountability, and physician-led execution. Stop collecting fragmented data and start acting on a ranked, strategic plan tailored to your biology and lifestyle.

👉 Discover the Premium Longevity Program and secure your health as your ultimate investment.